leisure time -WSS

leisure time

author：focus 2025-09-06 03:30:46 - browse：69546

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Biotech lab space demand falls sharply

focus

WSS

Experimental asthma app from Apple and Anthem shows promise

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Study suggests Covid rebound is far more common with Paxlovid than without

Readout LOUD podcast: possible new ALS drug, artificial wombs

White House drug czar issues call for 'recovery

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Tori Bowie and the unacceptable rates of Black maternal death

Intarcia’s device

United colonoscopy coverage change 'may cost lives,' doctors say

Lasker Awards 2023: Winners in biomedical research

Guidelines to prevent youth baseball injuries need more muscle

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Medical leaders decry Supreme Court decision on affirmative action

Ohio still needs to do more to protect the right to abortion

The cancer drug shortage isn’t new — and neither are the solutions

How AI helped researchers track recovery from depression

hotspot

Ukraine and a new approach to mental health in war

Medical student insurance fails on mental health care coverage

Why are Kaiser Permanente staff considering a strike?

Senate HELP committee spars over health care workforce policies

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

What is STAT's opinion section for?

focus

focus

knowledge

knowledge